// App-Quantinova.ai

9506 : Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.

Researchers

Presenter

  • Georgina V. Long

Principal Investigators

  • Jonathan S. Cebon

  • Michael B. Jameson

  • Bernie M. Fitzharris

  • Catriona M. McNeil

  • Andrew Graham Hill

  • Antoni Ribas

  • Michael B. Atkins

  • John A. Thompson

  • Wen-Jen Hwu

  • F. Stephen Hodi

  • Alexander M. Menzies

  • Alexander David Guminski

  • Richard Kefford

  • Xinxin Shu

  • Scot Ebbinghaus

  • Nageatte Ibrahim

  • Matteo S. Carlino

Medical Centers

  • Melanoma Institute Australia, the University of Sydney, Mater Hospital, and Royal North Shore Hospital, Sydney, Australia

  • Gallipoli Medical Research Foundation and Greenslopes Private Hospital, Brisbane, Australia

  • Olivia Newton-John Cancer Research Institute/ Austin Health, Heidelberg, Australia

  • Waikato Hospital, Hamilton, New Zealand

  • Canterbury District Health Board, Christchurch, New Zealand

  • Chris O'Brien Lifehouse, Royal Prince Alfred Hospital, Melanoma Institute Australia, The University of Sydney, Camperdown, Australia

  • Tasman Oncology Research, Southport, Australia

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • Seattle Cancer Care Alliance, Seattle, WA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Dana-Farber Cancer Institute, Boston, MA

  • Melanoma Institute Australia, Royal North Shore Hospital, The University of Sydney, North Sydney, Australia

  • Melanoma Institute Australia, the University of Sydney, Mater Hospital, and Royal North Shore Hospital, Sydney, Australia

  • Westmead Hospital, Melanoma Institute Australia, and Macquarie University, Sydney, Australia

  • Merck & Co., Inc., Kenilworth, NJ

  • Westmead and Blacktown Hospitals, Melanoma Institute Australia, Sydney, Australia

Locations

  • United States

  • New Zealand

  • Australia

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Ipilimumab

Outcome

  • Unknown

Study Design

  • Cohort

Phase

  • III

Study Id's

  • NCT02089685

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved